Business● Low1h ago · Nov 4, 2026, 12:17 AM
Alkermes reiterates $400M-$420M Q4 proprietary net sales outlook while targeting mid-2027 alixorexton Phase III data
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Alkermes has reiterated its Q4 proprietary net sales outlook between $400M-$420M. The company is also targeting mid-2027 for Phase III data related to alixorexton.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business20m agoCeriBell outlines $115M-$117M 2026 revenue, while launching delirium monitoring and previewing Omni for 2027Seeking Alpha TechBusiness29m agoToast raises full-year 2026 adjusted EBITDA outlook to $840M-$850M as it targets 26% recurring gross profit growthSeeking Alpha TechBusiness29m agoFinance of America forecasts $4-$5 run rate adjusted EPS in 2H 2027 as margins normalize in 1H 2027Seeking Alpha TechBusiness29m agoKey Tronic expects $8m annual labor savings while targeting return to profitability in H2 FY 2027Seeking Alpha Tech